BioWorld Asia

Feb. 25, 2004

InDex Signs $35M Agreement With Serono For Inflammation

InDex Pharmaceuticals AB signed its first product deal, out-licensing its antisense drug Kappaproct to Serono SA, of Geneva, for treatment of ulcerative colitis and other inflammatory conditions. (BioWorld International) Read More

Domantis Plans dAbs Trials With £17.5M In Second-Round Funds

Targeted Cancer Therapy Might Enter Clinical Trials Later In 2004

Borean Pharma Brings In ApoA-I Project Via Proteopharma Buyout

University Of Glasgow, Pharmetix Join Together To Start Grannus

EU Biotech Firms Worry New Rules Will Hinder Deal-Making

Graffinity Raises EUR15M In Third Round For Discovery Programs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 29, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...